強皮症の診断と治療市場：診断テスト、薬剤タイプ、治療薬、適応症別-2025-2030年の世界予測

強皮症の診断と治療市場は、2023年に20億9,000万米ドルと評価され、2024年には21億9,000万米ドルに達すると予想され、CAGR 6.25％で成長し、2030年には32億米ドルに達すると予測されています。

強皮症は慢性の結合組織疾患であり、診断と治療において独特な課題があり、市場範囲は病気の進行を管理することを目的とした高度な検出手法と治療オプションを包含しています。強固な診断の必要性は、強皮症の異質な性質にあり、他の自己免疫疾患と区別するために正確かつ早期の検出を必要とします。応用分野には、血清学的アッセイ、イメージング技術、個別化治療計画に不可欠なバイオマーカー同定が含まれます。最終用途分野は、臨床検査機関や研究機関から専門病院まで多岐にわたる。この市場に影響を与える主な成長要因としては、自己免疫疾患の有病率の増加、より精密な診断につながるバイオテクノロジーの進歩、個別化医療の重視の高まりなどが挙げられます。生物製剤や免疫療法へのシフトは、新興市場におけるヘルスケア・インフラの拡大と同様に、注目すべき機会を提供しています。企業は、非侵襲的診断ツールや標的療法の開発に焦点を当てた研究に投資することが推奨されます。戦略的提携や合併を伴う学術機関との共同研究は、競争上の優位性をもたらし、製品開発を加速させることができます。しかしながら、市場開拓は高い研究開発費、規制上のハードル、普遍的に有効な治療法の開発を妨げる強皮症の複雑な病態生理によって阻まれています。さらに、強皮症は希少疾患であるため、大規模臨床試験には課題があり、データの入手可能性や市場規模に影響を及ぼしています。革新的な分野としては、ゲノム研究やAIを活用した疾患進行の予測分析、自己免疫反応の調節におけるマイクロバイオームの役割の探求などが挙げられます。市場の特性として、高度な専門性が挙げられ、標準的な医療を再定義しうる画期的な進歩の機会も大きいが、持続可能な成長を達成するには、科学的、規制的、経済的状況を戦略的にナビゲートする必要があります。

市場力学：急速に進化する強皮症の診断と治療市場の主要市場インサイトを公開

強皮症の診断と治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 強皮症の有病率の増加と効果的な診断技術および治療法の必要性
  • 強皮症に対する意識の高まりと早期診断の重視
  • 新規薬剤や治療法開発のための臨床試験数の増加
• 市場抑制要因
  • 強皮症治療に伴う高コスト
• 市場機会
  • 画像診断技術やバイオマーカー同定などの診断技術の進歩
  • 強皮症の効率的な治療法を特定するための継続的研究
• 市場の課題
  • 強皮症治療に使用される薬剤に伴う副作用

ポーターのファイブフォース：強皮症の診断と治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：強皮症の診断と治療市場における外部からの影響の把握

外部マクロ環境要因は、強皮症の診断と治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析強皮症の診断と治療市場における競合情勢の把握

強皮症の診断と治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス：強皮症の診断と治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、強皮症の診断と治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：強皮症の診断と治療市場における成功への道筋を描く

強皮症の診断と治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 強皮症の罹患率の増加と効果的な診断技術および治療法の必要性
    • 強皮症の症状に関する認識の高まりと早期診断の重要性
    • 新薬や治療法の開発に向けた臨床試験の増加
  • 抑制要因
    • 強皮症治療に伴う高額な費用
  • 機会
    • 画像技術やバイオマーカーの特定などの診断技術の進歩
    • 強皮症の効果的な治療法を特定するための継続的な調査
  • 課題
    • 強皮症治療に使用される薬剤に関連する副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 強皮症の診断と治療市場診断テスト別

• 血液検査
• イメージング
  • CTスキャン
  • MRI
  • X線検査
• 肺機能検査
• 皮膚生検

第7章 強皮症の診断と治療市場薬の種類別

• カルシウムチャネル遮断薬
• キレート剤
• コルチコステロイド
• エンドセリン受容体作動薬
• 免疫抑制剤
• PDE-5阻害剤
• プロスタサイクリン類似体

第8章 強皮症の診断と治療市場セラピューティクス

• 生物学的療法
• 遺伝子治療
• 肺線維症の治療
• レイノー現象の管理
• 幹細胞移植

第9章 強皮症の診断と治療市場適応症別

• ローカライズ
• 全身的

第10章 南北アメリカの強皮症の診断と治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の強皮症の診断と治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの強皮症の診断と治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Antibodies Inc.
• AstraZeneca plc
• Bayer AG
• Bio-Rad Laboratories, Inc
• Biogen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Eli Lilly and Company
• Exagen Inc.
• F. Hoffmann-La Roche Ltd.
• Galapagos NV
• Gilead Sciences, Inc.
• GlaxoSmithKline plc（GSK）
• Merck & Co., Inc.
• Myriad Genetics, Inc
• Novartis AG
• PerkinElmer Inc.
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi Genzyme
• Takeda Pharmaceutical Company Limited
• The Bristol-Myers Squibb Company
• Thermo Fisher Scientific Inc.
• Trinity Biotech plc.

LIST OF FIGURES

• FIGURE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CT SCANS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHELATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ENDOTHELIN RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PDE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTACYCLIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FIBROSIS TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RAYNAUD'S PHENOMENON MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LOCALIZED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 50. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 51. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 52. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 53. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 77. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 78. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 79. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 80. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 82. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 83. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 85. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 168. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 169. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 170. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 171. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 188. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 189. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 190. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 191. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 193. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 194. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 195. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 196. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 242. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 243. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Scleroderma Diagnostics & Therapeutics Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.19 billion in 2024, and is projected to grow at a CAGR of 6.25%, to USD 3.20 billion by 2030.

Scleroderma, a chronic connective tissue disease, presents unique challenges in diagnostics and therapeutics, with the market scope encompassing advanced detection methodologies and therapeutic options aimed at managing the disease progression. The necessity of robust diagnostics lies in the heterogeneous nature of scleroderma, requiring precise and early detection to differentiate from other autoimmune conditions. Application areas include serological assays, imaging technologies, and biomarker identification, integral for personalized treatment plans. End-use sectors range from clinical laboratories and research institutions to specialty hospitals. Key growth factors influencing this market include increasing prevalence of autoimmune disorders, advancements in biotechnology leading to more precise diagnostics, and a growing emphasis on personalized medicine. The shift towards biologics and immunotherapies presents notable opportunities, as does the expanding healthcare infrastructure in emerging markets. Companies are recommended to invest in research focused on developing non-invasive diagnostic tools and targeted therapies. Collaborations with academic institutions for research, coupled with strategic partnerships or mergers, can offer competitive advantages and accelerate product development. However, market growth is challenged by high R&D costs, regulatory hurdles, and the complex pathophysiology of scleroderma that hampers the development of universally effective treatments. Additionally, the rarity of the disease poses challenges for large-scale clinical trials, impacting data availability and market scale. Innovation areas include genomic research and leveraging AI for predictive analytics in disease progression, as well as exploring the microbiome's role in autoimmune response modulation. The market nature is characterized by a high degree of specialization with significant opportunities for breakthroughs that could redefine standards of care but requires strategic navigation through scientific, regulatory, and economic landscapes to achieve sustainable growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Scleroderma Diagnostics & Therapeutics Market

The Scleroderma Diagnostics & Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of scleroderma and the need for effective diagnostic techniques and therapies
  • Growing awareness about scleroderma condition and emphasis on early diagnosis
  • Rising number of clinical trials for the development of novel drugs and therapies
• Market Restraints
  • High cost associated with scleroderma treatment
• Market Opportunities
  • Advancements in diagnostic technologies, such as imaging techniques and biomarker identification
  • Ongoing research for identifying efficient treatment options for scleroderma
• Market Challenges
  • Side effects associated with the drugs used in scleroderma treatment

Porter's Five Forces: A Strategic Tool for Navigating the Scleroderma Diagnostics & Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Scleroderma Diagnostics & Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Scleroderma Diagnostics & Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Scleroderma Diagnostics & Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Scleroderma Diagnostics & Therapeutics Market

A detailed market share analysis in the Scleroderma Diagnostics & Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Scleroderma Diagnostics & Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Scleroderma Diagnostics & Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Scleroderma Diagnostics & Therapeutics Market

A strategic analysis of the Scleroderma Diagnostics & Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Scleroderma Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Antibodies Inc., AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Inc, Biogen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd., Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Myriad Genetics, Inc, Novartis AG, PerkinElmer Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Takeda Pharmaceutical Company Limited, The Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., and Trinity Biotech plc..

Market Segmentation & Coverage

This research report categorizes the Scleroderma Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Diagnostic Tests, market is studied across Blood Tests, Imaging, Pulmonary Function Tests, and Skin Biopsies. The Imaging is further studied across CT Scans, MRI, and X-rays.
• Based on Drug Type, market is studied across Calcium Channel Blockers, Chelating Agents, Corticosteroids, Endothelin Receptor Agonists, Immunosuppressive Agents, PDE-5 Inhibitors, and Prostacyclin Analogues.
• Based on Therapeutics, market is studied across Biologic Therapies, Gene Therapy, Pulmonary Fibrosis Treatments, Raynaud's Phenomenon Management, and Stem Cell Transplantation.
• Based on Indication, market is studied across Localized and Systemic.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of scleroderma and the need for effective diagnostic techniques and therapies
    • 5.1.1.2. Growing awareness about scleroderma condition and emphasis on early diagnosis
    • 5.1.1.3. Rising number of clinical trials for the development of novel drugs and therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with scleroderma treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in diagnostic technologies, such as imaging techniques and biomarker identification
    • 5.1.3.2. Ongoing research for identifying efficient treatment options for scleroderma
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with the drugs used in scleroderma treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Scleroderma Diagnostics & Therapeutics Market, by Diagnostic Tests

• 6.1. Introduction
• 6.2. Blood Tests
• 6.3. Imaging
  • 6.3.1. CT Scans
  • 6.3.2. MRI
  • 6.3.3. X-rays
• 6.4. Pulmonary Function Tests
• 6.5. Skin Biopsies

7. Scleroderma Diagnostics & Therapeutics Market, by Drug Type

• 7.1. Introduction
• 7.2. Calcium Channel Blockers
• 7.3. Chelating Agents
• 7.4. Corticosteroids
• 7.5. Endothelin Receptor Agonists
• 7.6. Immunosuppressive Agents
• 7.7. PDE-5 Inhibitors
• 7.8. Prostacyclin Analogues

8. Scleroderma Diagnostics & Therapeutics Market, by Therapeutics

• 8.1. Introduction
• 8.2. Biologic Therapies
• 8.3. Gene Therapy
• 8.4. Pulmonary Fibrosis Treatments
• 8.5. Raynaud's Phenomenon Management
• 8.6. Stem Cell Transplantation

9. Scleroderma Diagnostics & Therapeutics Market, by Indication

• 9.1. Introduction
• 9.2. Localized
• 9.3. Systemic

10. Americas Scleroderma Diagnostics & Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Scleroderma Diagnostics & Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Antibodies Inc.
• 4. AstraZeneca plc
• 5. Bayer AG
• 6. Bio-Rad Laboratories, Inc
• 7. Biogen Inc.
• 8. Boehringer Ingelheim Pharmaceuticals, Inc.
• 9. Eli Lilly and Company
• 10. Exagen Inc.
• 11. F. Hoffmann-La Roche Ltd.
• 12. Galapagos NV
• 13. Gilead Sciences, Inc.
• 14. GlaxoSmithKline plc (GSK)
• 15. Merck & Co., Inc.
• 16. Myriad Genetics, Inc
• 17. Novartis AG
• 18. PerkinElmer Inc.
• 19. Pfizer Inc.
• 20. Regeneron Pharmaceuticals, Inc.
• 21. Sanofi Genzyme
• 22. Takeda Pharmaceutical Company Limited
• 23. The Bristol-Myers Squibb Company
• 24. Thermo Fisher Scientific Inc.
• 25. Trinity Biotech plc.